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Increased Central Venous
Pressure Is Associated With Impaired
Renal Function and Mortality in a Broad
Spectrum of Patients With Cardiovascular Disease
Kevin Damman, MD,* Vincent M. van Deursen,* Gerjan Navis, MD, PHD,†
Adriaan A. Voors, MD, PHD,* Dirk J. van Veldhuisen, MD, PHD, FACC,*
Hans L. Hillege, MD, PHD*‡
Groningen, the Netherlands
Objectives We sought to investigate the relationship between increased central venous pressure (CVP), renal function, and
mortality in a broad spectrum of cardiovascular patients.
Background The pathophysiology of impaired renal function in cardiovascular disease is multifactorial. The relative impor-
tance of increased CVP has not been addressed previously.
Methods A total of 2,557 patients who underwent right heart catheterization in the University Medical Center Groningen,
the Netherlands, between January 1, 1989, and December 31, 2006, were identified, and their data were ex-
tracted from electronic databases. Estimated glomerular filtration rate (eGFR) was assessed with the simplified
modification of diet in renal disease formula.
Results Mean age was 59  15 years, and 57% were men. Mean eGFR was 65  24 ml/min/1.73 m2, with a cardiac
index of 2.9  0.8 l/min/m2 and CVP of 5.9  4.3 mm Hg. We found that CVP was associated with cardiac in-
dex (r  0.259, p  0.0001) and eGFR (r  0.147, p  0.0001). Also, cardiac index was associated with
eGFR (r  0.123, p  0.0001). In multivariate analysis CVP remained associated with eGFR (r  0.108,
p  0.0001). In a median follow-up time of 10.7 years, 741 (29%) patients died. We found that CVP was an in-
dependent predictor of reduced survival (hazard ratio: 1.03 per mm Hg increase, 95% confidence interval: 1.01
to 1.05, p  0.0032).
Conclusions Increased CVP is associated with impaired renal function and independently related to all-cause mortality in a
broad spectrum of patients with cardiovascular disease. (J Am Coll Cardiol 2009;53:582–8) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.080h
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cenal dysfunction is a strong and independent predictor of
rognosis in the general population but also in patients with
iabetes, hypertension, coronary artery disease, and heart
ailure (1–7). The pathophysiology is multifactorial and
ssociated with decreased renal perfusion, atherosclerosis
nd inflammation, endothelial dysfunction, and neurohor-
onal activation (8–10). We recently showed that in
atients with cardiac dysfunction secondary to pulmonary
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008, accepted August 18, 2008.ypertension, not only was renal perfusion strongly associ-
ted with renal function impairment but also with venous
ongestion (11). However, it is unclear whether this obser-
ation is limited to those patients with reduced cardiac
unction and pulmonary hypertension or whether it also
ay be present in patients with a mixture of cardiovascular
iseases with varying etiologies and treatments. In addition,
here are only limited data on the relationship between
See page 597
enous congestion, as estimated by central venous pressure
CVP) and the impact on prognosis, even in patients with
nd without heart failure. The studies that have been
onducted are either small or include only noninvasive
ssessment of increased venous congestion, such as jugular
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February 17, 2009:582–8 Central Venous Pressure and Renal Functionenous pressure (12–15). In the present study, we therefore
imed to investigate the relationship between CVP, renal
unction, and mortality in patients with a mixture of
ardiovascular diseases with varying etiologies and
reatments.
ethods
ase identification. Using the patient registration system
f the University Medical Center Groningen, the Nether-
ands, all patients that underwent right heart catheterization
etween January 1, 1989, and December 31, 2006, were
dentified.
ata extraction. Retrospective chart review was performed
o analyze characteristics of all patients that were identified
uring the electronic search. For each patient, date of birth,
ex, race, and weight and height were collected. Comorbid
onditions, including hypertension, coronary artery disease,
ardiac valve disease, congenital heart disease, history of
troke, hypercholesterolemia, and diabetes, in addition to
edical treatment at the time of catheterization also were
xtracted for each patient. Furthermore, the reason for
erforming right heart catheterization was identified. The
tudy was approved by the institutional review board of the
niversity Medical Center Groningen.
eart catheterization. Hemodynamic variables obtained
uring catheterization included systolic blood pressure (mm
g), diastolic blood pressure (mm Hg), cardiac output
thermodilution, l/min), and right atrial pressure as indicator
f CVP (CVP, mm Hg). Cardiac index (l/min/m2) was
etermined as cardiac output divided by the body surface area,
hich was calculated as: 0.007184·weight0.425·length0.725.
easurements obtained from cardiac catheterization were
btained from the patient during a resting state.
enal function measurement. Serum creatinine at the day
f catheterization was extracted. For the patients who did
ot have laboratory measurements on the day of catheter-
zation, measurements obtained within 3 days before cath-
terization were taken as the baseline value. Of patients
ncluded in the study, 2,282 (89%) had at least 1 serial
reatinine measurement within 3 days of catheterization.
enal function was estimated as glomerular filtration rate
GFR) by using the simplified modification of diet in renal
isease equation (estimated glomerular filtration rate
eGFR] [ml/min/1.73 m2]  186.3  [serum creati-
ine]1.154  age0.203  [0.742 if female]) (16). Esti-
ated GFR values 200 ml/min/1.73 m2 were set equal to
00 ml/min/1.73 m2, according to Coresh et al. (17).
ortality data. Survival status was determined using the
lectronic patient registration database of the University
edical Center Groningen. Follow-up started directly after
ight heart catheterization. The primary end point consisted
f death from any cause.
tatistical analysis. Data are given as mean  standard
eviation when normally distributed, as median and inter-
uartile range when skewed distributed, and as frequenciesnd percentages for categorical
ariables. Associations between
aseline variables were evaluated
y means of 1-way analysis of
ariance, the Kruskal-Wallis test,
nd chi-square or Fisher exact
ests, when appropriate. Two-
ided p values were used, taking
 0.05 to be statistically sig-
ificant. CVP was divided into
ertiles to assess relationships between baseline characteris-
ics and CVP. A fractional polynomial parameterization of
xposure was used to explore nonlinearity between different
redictors and renal function. In this technique, each
xposure value is expressed as a polynomial of degree 1
e.g., quadratic, cubic, and so on), yielding an estimated
odel with multiple predictors (i.e., separate predictors for
he linear, quadratic, terms, respectively). We used a Cox
roportional hazards survival model to estimate hazard
atios (HRs) with 95% confidence intervals (CIs). At first,
n multivariate analysis, CVP was fitted into a stepwise
ultivariate Cox regression analysis on a continuous scale.
n secondary analysis, CVP was fitted into the model and, in
ultiple steps, the model was adjusted for other variables
nd parameters. The internal validity of the regression
odel was assessed by the bootstrap resampling technique
18). For each of 100 bootstrap samples, the model was
efitted and tested on the original sample to obtain a
ias-corrected estimate of predictive accuracy. Statistical
nalyses were performed using SPSS version 12.0 (Chicago,
llinois) and STATA version 9.0 (College Station, Texas).
esults
aseline characteristics. A total of 3,757 right heart cath-
terizations were conducted between 1989 and 2006. Of
hese, 2,557 (68%) were first or only right heart catheter-
rimary Indication for Heart Catheterization
Table 1 Primary Indication for Heart Catheterization
Percentage of Patients
Aortic valve disorders 29
Aortic valve stenosis 23
Aortic valve insufficiency 6
Mitral valve disorders 15
Mitral valve insufficiency 14
Mitral valve stenosis 1
Pulmonary valve disorders 1
Pulmonary valve insufficiency 0.8
Pulmonary valve stenosis 0.2
Heart failure 16
Coronary artery disease 13
Pre-transplantation (noncardiac) 11
Rhythm disorders 5
Pulmonary hypertension 3
Congenital heart disease 2
Post-heart transplantation 2
Abbreviations
and Acronyms
CI  confidence interval
CVP  central venous
pressure
eGFR  estimated
glomerular filtration rate
HR  hazard ratioOther 6
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Central Venous Pressure and Renal Function February 17, 2009:582–8zation of unique patients and formed the study population.
ain reasons for right heart catheterization are shown in
able 1. Aortic and mitral valve disorders accounted for
4% of indications, whereas in 16%, acute or chronic heart
ailure was the predominant reason. Mean age was 59  15
Figure 1 Distribution of CVP and Curvilinear Relationship
Between CVP and eGFR in the Study Population
Adjusted for age, sex, and cardiac index. The curvilinear model had the follow-
ing individual polynomial components for the relationship between CVP and
eGFR: First order: Y  25.8·(CVP  1)/10 (Wald 28.2, p  0.0001) and sec-
ond order: Y  35.7·([CVP  1]/10)0.5 (Wald 17.4, p  0.0001). CVP  cen-
tral venous pressure, eGFR  estimated glomerular filtration rate.
aseline Characteristics According to Tertiles of CVP
Table 2 Baseline Characteristics According to Tertiles of CVP
Total Tertile 1 (0 to 3 mm Hg)
n 2,557 911
Age (yrs) 59 15 60 15
Sex (% male) 57 59
SBP (mm Hg) 133 29 133 28
DBP (mm Hg) 68 13 66 12
CO (l/min) 5.5 1.6 5.7 1.6
Cardiac index (l/min/m2) 2.9 0.8 3.1 0.7
CVP (mm Hg) 5.9 4.3 2 1
eGFR (ml/min/1.73 m2) 65 24 65 23
Medical history (%)
Heart failure 16 15
Coronary artery disease 24 24
Congenital heart disease 5 4
Valve disease 51 50
Hypercholesterolemia 6 7
Diabetes mellitus 9 8
Hypertension 20 21
Stroke 5 4
Medication (%)
Diuretics 42 37
Beta-blocker 28 25
ACEI or ARB 38 36
Aldosterone antagonist 9 5
CEI angiotensin-converting enzyme inhibitor; ARB angiotensin-II receptor blocker; CO cardi
ltration rate; NS  not significant; SBP  systolic blood pressure.tears, and 57% were men (Table 2). In the total study
opulation, both mean cardiac index (2.9  0.8 l/min/m2)
nd mean CVP (5.9 4.3 mm Hg) were within the normal
ange. The distribution of CVP among the study population
s shown in Figure 1. Mean eGFR was moderately im-
aired: 65  24 ml/min/1.73 m2.
The distribution of different factors over tertiles of CVP
s shown in Table 2. Most of the characteristics were equally
istributed across tertiles of CVP, except for the highest
ertile (CVP 6 mm Hg). Both cardiac output and cardiac
ndex were significantly lower in the highest tertile com-
ared with lower tertiles (p 0.0001), corresponding to r
0.259 (p  0.0001) for the association between CVP and
ardiac index. Furthermore, patients in the highest tertile
ere treated more frequently with angiotensin-converting
nzyme inhibitor/angiotensin-II receptor blockers, beta-
lockers, diuretics, and aldosterone antagonists. Prevalence
f heart failure showed a trend toward increasing with
igher tertiles of CVP (p  0.0781), whereas congenital
eart disease was also more prevalent in the highest tertile.
inally, eGFR was significantly lower in the highest tertile
f CVP, compared with both lower tertiles (p  0.001).
urvilinear fitting and the relationship between CVP
nd eGFR. Figure 1 shows the curvilinear relationship
etween CVP and eGFR in the total study population as
btained by fractional polynomial modeling. Estimated
FR showed a small increase when CVP increased from 1
ertile 2 (4 to 6 mm Hg) Tertile 3 (>6 mm Hg) p Value for Trend
855 791
59 15 58 15 0.0032
58 54 NS
134 27 129 31 0.0100
68 12 69 13 0.0010
5.5 1.5 5.0 1.5 0.0001
3.0 0.7 2.7 0.8 0.0001
5 1 11 4 0.0001
67 24 62 24 0.0001
15 19 NS
25 24 NS
5 7 0.0189
55 49 NS
5 6 NS
8 10 NS
20 18 NS
5 6 NS
38 53 0.0001
29 31 0.0388
32 45 0.0001
6 15 0.0001
ut; CVP central venous pressure; DBP diastolic blood pressure; eGFR estimated glomerularT
ac outpo 6 mm Hg. However, in CVP values 6 mm Hg, a steep
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February 17, 2009:582–8 Central Venous Pressure and Renal Functionecrease is observed with increasing CVP values. This
nding resulted in a partial correlation of r  0.064, p 
.0218 in patients with CVP 6 mm Hg, and r  0.212,
 0.0001 in patients with CVP 6 mm Hg (adjusted for
ge, sex, and cardiac index). On a continuous scale, CVP
as also significantly associated with eGFR (r  0.110,
 0.0001) after transformation.
Besides CVP, age (r  0.438, p  0.0001), sex (r 
.137, p  0.0001), and cardiac index (r  0.249, p 
.0001) were associated with eGFR. In addition, lower
GFR values also were found to be related with the use of
ny type of cardiovascular medication and a history of
iabetes and hypertension. There was a significant interac-
ion between CVP and cardiac index on the relationship
ith eGFR. The observed biphasic relationship between
VP and eGFR was most pronounced in patients with
elatively normal cardiac index (Fig. 2).
In multivariate analysis, CVP remained associated with
GFR (r  0.108, p  0.0001, adjusted for covariates),
hich was confirmed by bootstrap analysis (Online Table
). After adjustment for the year of catheterization, the
ssociation between CVP and eGFR was numerically un-
hanged: r  0.105, p  0.0001. Excluding patients with
history of heart transplantation, who were likely to receive
enal function compromising immunotherapy, CVP re-
ained associated with eGFR (r  0.108, p  0.0001) in
ultivariate analysis. Including only patients without heart
ailure, similar associations were present (r  0.080, p 
.0034). Excluding both heart transplant recipients and
eart failure patients, the association between CVP and
GFR remained (r  0.079, p  0.0042).
VP and mortality. Mortality data were available in all
atients, whereas time of death was available in 2,424 (95%)
f patients. Median follow-up among survivors was 10.7
Figure 2 Curvilinear Relationship Between CVP and
eGFR According to Different Cardiac Index Values
p  0.0217 for interaction between cardiac index and CVP on the relationship
with eGFR. Solid line  cardiac index 2.5 l/min/m2; dashed line  cardiac
index 2.5 to 3.2 l/min/m2; dotted line  cardiac index 3.2 l/min/m2. Abbre-
viations as in Figure 1.cears and, during follow-up, 741 (29%) of the patients died.
rude mortality ranged from 24% in the lowest tertile to
9% and 35% in the 2 highest tertiles of CVP (p  0.0001
or trend). On a continuous scale, greater CVP levels were
ssociated with impaired survival (HR: 1.05 per mm Hg
ncrease, 95% CI: 1.04 to 1.07, p  0.0001). Kaplan-Meier
urvival curves for tertiles of CVP are shown in Figure 3,
howing that patients with the greatest CVP in particular
ere at risk for increased mortality (HR for CVP 6 mm
g vs. 6 mm Hg: 1.49, 95% CI: 1.26 to 1.76, p 
.0001). Baseline eGFR (HR: 1.09 per 10 ml/min/1.73 m2
ecrease, 95% CI: 1.05 to 1.13, p  0.0001) and cardiac
ndex (HR: 0.74 per l/min/m2 increase, 95% CI: 0.66 to
.84, p  0.0001) also were strong predictors of mortality.
ther factors associated with reduced survival are shown in
able 3. In stepwise multivariate Cox regression analysis,
VP remained significantly associated with reduced survival
HR: 1.03 per mm Hg increase, 95% CI: 1.01 to 1.05,
 0.0032) (Table 3). Finally, we fitted a second model,
djusting CVP for other covariates (Online Table 2). CVP
emained an independent predictor of impaired survival
HR: 1.03 per mm Hg increase, 95% CI: 1.01 to 1.05, p 
.0144). To account for the effects of changing therapy
uring the study inclusion time, we adjusted for the year of
atheterization. This secondary analysis yielded similar re-
ults (HR: 1.03 per mm Hg increase, 95% CI: 1.00 to 1.05,
 0.0207). Excluding patients with known heart failure
nd heart transplant recipients, CVP was still associated
ith mortality (HR: 1.03 per 5 mm Hg increase, 95% CI:
.00 to 1.06, p  0.0369).
iscussion
he present study shows that increased CVP is associated
ith impaired renal function in a broad spectrum of
Figure 3 Kaplan-Meier Analysis of Event-Free
Survival According to Tertiles of CVP
HR: 1.22 (95% CI: 1.00 to 1.49), p  0.0466 for CVP 4 to 6 mm Hg; HR:
1.65 (95% CI: 1.35 to 2.01), p  0.0001 for CVP 6 mm Hg, both compared
with CVP 0 to 3. CI  confidence interval; HR  hazard ratio; other abbrevia-
tions as in Figure 1.ardiovascular patients who underwent right heart catheter-
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Central Venous Pressure and Renal Function February 17, 2009:582–8zation. In addition, the slope between CVP and impaired
GFR was steeper with relatively preserved cardiac function.
inally, an increased CVP was a strong and independent
eterminant of all-cause mortality, which was especially
bserved in patients with a CVP 6 mm Hg.
There are only limited data on the relationship between
ncreased CVP and renal impairment. Studies in animals
ave shown that increasing renal venous pressure leads to a
eduction in glomerular filtration, which was probably
ediated by a decreased renal perfusion (19). Renal vein
onstriction led to a decrease in GFR in rats (20), whereas
enal function decreased when renal vein pressure was
ncreased in dogs, but only when cardiac output was reduced
21). We recently showed that in patients with reduced
ardiac function, secondary to pulmonary hypertension,
ncreased CVP was strongly associated with renal impair-
ent, especially when renal perfusion was already impaired
11). Early studies on increased renal vein pressure in heart
ailure patients and animals showed a marked reduction in
enal blood flow as well as water and salt excretion
22,23), but the effect on GFR was not uniform. One
mall report showed a strong relationship between CVP
nd renal blood flow in advanced heart failure (24).
Drazner et al. (13) reported that in patients with in-
reased jugular venous pressure on examination, serum
reatinine was significantly greater. In patients who under-
ent elective cardiac surgery, pre-operative presence of high
VP was a strong predictor of the occurrence of acute renal
njury, independent of the presence of low CO (25).
However, especially in patients with preserved cardiac
unction, data regarding the relationship between CVP and
enal function are scarce. Diastolic dysfunction, a disease
ultivariate Stepwise Cox Regression Model
Table 3 Multivariate Stepwise Cox Regression Model
Univariate
Variables Hazard Ratio (95% CI)
Age (per 10 yr increase) 1.05 (1.00–1.10)
Sex 1.03 (0.88–1.20)
Cardiac index (per l/min/m2 increase) 0.74 (0.66–0.84)
CVP (per mm Hg increase) 1.05 (1.04–1.07)
eGFR (per 10 ml/min/1.73 m2 decrease) 1.09 (1.05–1.13)
Medication
Diuretic use 1.43 (1.22–1.67)
ACEI or ARB use 1.29 (1.10–1.52)
Aldosterone antagonist use 1.92 (1.50–2.45)
Medical history (%)
Coronary artery disease 1.26 (1.05–1.50)
Diabetes mellitus 1.83 (1.44–2.31)
Indication for catheterization
Aorta insufficiency 0.63 (0.43–0.93)
Congenital heart disease 0.36 (0.17–0.77)
Pre-transplantation (noncardiac) 1.50 (1.21–1.85)
Heart failure 1.48 (1.21–1.85)
Rhythm disorders 0.49 (0.29–0.82)
I  confidence interval; other abbreviations as in Table 2.haracterized by increased filling pressures, often coexists pith renal failure and vice versa (26–28). Interestingly, a
ecent study showed that renal dysfunction is even more
mportant in defining mortality risk in patients with pre-
erved cardiac function compared with those with systolic
ysfunction (29,30). Our present study confirmed that
ncreased CVP is an important risk factor for decreased
enal function in patients with preserved and decreased
ardiac function.
urvilinear effect of CVP with eGFR. We observed a
iphasic relationship between eGFR and increasing CVP.
n the physiologic ranges of CVP, up to 6 mm Hg, eGFR
ncreases gradually. This subtle increase in eGFR may be a
eflection of increased cardiac filling to preserve cardiac
unction by Frank-Starling mechanism (pre-load), and sub-
equent renal perfusion (31). This gradual increase in eGFR
as observed across the full spectrum of low to high cardiac
ndex. We observed a decrease in eGFR when CVP
ncreases above 6 mm Hg. In these patients, the equilibrium
mong venous return, CO, and CVP may have shifted
oward a plateau phase or optimum, where CO is not
urther increased in response to greater CVP (32).
reater CVP levels will then decrease renal perfusion
ressure, which will further impair eGFR. However, if
reater CVP levels preserve CO, and despite this mech-
nism, eGFR decreases with greater CVP, this action
uggests that increased CVP also may exert an effect on
FR in this group of patients, independent of renal
erfusion.
Importantly, the relationship between CVP and GFR is
ound to be bidirectional. Not only may CVP influence
FR, but even mildly impaired renal function may initiate
alt and water retention, resulting in increased cardiac filling
Multivariate
alue Hazard Ratio (95% CI) Wald Statistic p Value
880 1.21 (1.12–1.31) 25.4 0.0001
13
001 0.81 (0.71–0.93) 9.1 0.0026
001 1.03 (1.01–1.05) 8.7 0.0032
001
001
017
001 1.50 (1.10–2.02) 6.9 0.0087
112
001 1.76 (1.34–2.31) 16.6 0.0001
203
078
001 2.54 (1.90–3.40) 39.2 0.0001
001 1.71 (1.34–2.20) 18.1 0.0001
062p V
0.0
0.7
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0ressures (33). Because of the cross-sectional nature of our
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February 17, 2009:582–8 Central Venous Pressure and Renal Functionnalysis, we were unable to investigate the cause-effect
ssociations, and our present analysis must be regarded as
ypothesis generating.
VP and eGFR in patients with and without cardiac
ysfunction. Of particular interest is the interaction be-
ween cardiac index and CVP on eGFR. Patients who have
combination of reduced perfusion (cardiac index) and
ncreased venous congestion (CVP) suffer from fluid over-
oad and decreased organ perfusion, leading, among other
hings, to renal dysfunction. We showed that patients with
igh CVP levels often also have decreased cardiac index and
educed eGFR. Remarkably, CVP and cardiac index
howed an interaction on the relationship with eGFR, with
n even more pronounced relationship in patients with
elatively normal cardiac index. This further strengthens the
bservation of a relationship between CVP and eGFR,
hich is not exclusively due to reduced cardiac systolic
unction. It also challenges the intuitive notion that fluid
verload, although deleterious from a cardiovascular per-
pective, will invariably be beneficial from the point of view
f preservation of renal function. Because our analysis does
ot allow to dissect cause and effect relationships, however,
t might also well be that the relatively normal cardiac index
s maintained at the expense of the increased CVP. In that
ase, apparently, such a renal hemodynamic profile does not
ranslate into better renal function. Our present findings
eem inconsistent with our earlier findings, showing that
atients with reduced renal perfusion in particular are prone
o a detrimental effect of CVP on GFR (11). However, we
id not measure renal hemodynamics or renal function by
learance techniques in the present study, and the popula-
ion was also different. Furthermore, our previous study
onsisted of patients with much lower cardiac indexes, all of
hich makes a comparison difficult. Nevertheless, this
nconsistency needs to be further addressed in future studies.
New therapeutic agents in the treatment of acute heart
ailure that are specifically targeted at improvement of
ardiac function and reducing venous congestion recently
ave shown promising results regarding renal function. A
ubstudy of the SURVIVE (Survival of Patients With Acute
eart Failure in Need of Intravenous Inotropic Support)
tudy, in which levosimendan was compared with dobut-
mine, showed that improvement of renal function was
ore pronounced in the group receiving levosimendan,
espite the obvious positive inotropic effect of dobutamine
34). The specific venodilatory effect observed with levosi-
endan, with subsequent reduced CVP, may be the patho-
hysiologic mechanism, supporting a direct pathophysio-
ogic link between CVP and renal impairment (35).
VP and mortality. Increased CVP and jugular venous
ressure predispose to the development of heart failure in
atients with cardiac dysfunction and have been associated
ith reduced survival in patients with heart failure
12,13,36). Small studies have shown that invasive assess-
ent of CVP is a predictor of cardiovascular outcome inatients with advanced heart failure (14,15). In other selected patient populations, such as patients who under-
ent Fontan surgery or lung transplantation, greater CVPs
ere strong predictors of outcome (37,38). The prognostic
mportance of increased CVP in patients with normal
ardiac function has not been reported previously. We show
hat in a selected patient population, increased CVP re-
ained a determinant of all-cause mortality, independent of
ardiac function. This association with mortality was most
rominent in patients with severely increased CVP, even
fter adjustment for other baseline characteristics. This
nding was additive to the observation that greater CVP
evels predispose to lower eGFR, which may influence
urvival by different mechanisms.
linical implications. Increased CVP frequently is ob-
erved in patients with and without reduced cardiac func-
ion, comprising almost 20% of patients in the present
atient population. Recognition of these patients is essential
ecause not only is renal dysfunction much more frequently
bserved, but the risk of mortality also increases with
ncreasing CVP levels. Treatment to selectively lower CVP
ay be favorable to reduce symptoms and signs of conges-
ion, improve GFR, and improve prognosis.
tudy limitations. The present study comprises a se-
ected patient population that had a specific indication for
ight heart catheterization. Patients undergoing right
eart catheterization are prone to have greater right-
ided filling pressures, and the present observations may
herefore not represent the general cardiovascular popu-
ation. However, this is a large cohort study, with invasive
ardiac function and CVP measurements across the full
ange. Second, this is a retrospective analysis, and no
nvasive data are available on renal blood flow and true
FR in these patients. Furthermore, it should be ad-
ressed that our study population had very different
atheterization indications, medical history, and medica-
ion regime, all of which could have influenced our
esults. In our study, the presence of heart failure was a
linical diagnosis, rather than related to reduced cardiac
ndex on catheterization. Therefore, the prevalence of
eart failure in our study is most likely underestimated.
he relationship between increased CVP and renal per-
usion has been observed in heart failure. However our
resent study is the first to show an independent effect of
VP on renal function. Finally, the retrospective nature
f this study and the cross-sectional design limited our
bility to investigate the cause-effect relationship between
enal impairment and increased CVP, which may actually
utually influence each other.
onclusion
ncreased CVP is associated with impaired renal function
nd is independently related to all-cause mortality in a broad
pectrum of patients with cardiovascular disease.
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